Valuation: Pulmatrix, Inc.

Market Cap 55.51L 47.62L 44.47L 40.8L 76.72L 53Cr 77.98L 5.25Cr 2.05Cr 27Cr 2.08Cr 2.04Cr 88Cr P/E 2024
-2.67x
P/E 2025 -1.58x
Enterprise Value 14.63L 12.55L 11.72L 10.75L 20.22L 14Cr 20.56L 1.38Cr 54.16L 7.02Cr 54.95L 53.75L 23Cr EV / Sales 2024
2.05x
EV / Sales 2025 -
Free-Float
99.23%
Yield 2024 *
-
Yield 2025 -
1 day-1.94%
1 week-5.00%
Current month-12.64%
1 month-10.06%
3 months+20.63%
6 months-44.53%
Current year-31.84%
1 week 1.5
Extreme 1.495
1.62
1 month 1.45
Extreme 1.45
1.8
Current year 1.16
Extreme 1.16
3.4
1 year 1.16
Extreme 1.16
5.5
3 years 1.16
Extreme 1.16
10.4
5 years 1.16
Extreme 1.16
20.8
10 years 1.16
Extreme 1.16
1,396
Manager TitleAgeSince
Chief Executive Officer 70 20/07/2024
Director TitleAgeSince
Director/Board Member 58 01/11/2019
Director/Board Member 57 23/06/2020
Director/Board Member 55 01/10/2020
Date Insider Type Main position Quantity % Market Cap.
26/01/23 Free

Chairman

2,436 0.0669%
26/01/23 Free

Director

1,700 0.0467%
26/01/23 Free

Director

1,700 0.0467%
Change 5-day change 1-year change 3-year change Capi.($)
-1.94%-5.00%-67.10%-38.99% 55.51L
-1.90%+3.12%+81.70%+110.88% 7.22TCr
-0.87%+15.43%+54.62%+90.92% 6.4TCr
+1.71%-1.22%+2.71%+501.29% 2.85TCr
+3.63%+8.57%+62.12%+24.72% 2.51TCr
+21.96%+21.98%+1.54%+2.50% 2.84TCr
-0.07%+6.37%+39.55%-13.67% 2TCr
0.00%-2.78%+247.46%+423.83% 1.82TCr
+1.81%+1.43%+23.67%+527.06% 1.6TCr
+2.39%+7.96%+44.96%+157.77% 1.35TCr
Average +0.24%+5.15%+49.12%+178.63% 2.86TCr
Weighted average by Cap. -0.20%+6.69%+60.69%+163.68%

Financials

2024 2025
Net sales 78.06L 66.96L 62.53L 57.37L 1.08Cr 75Cr 1.1Cr 7.38Cr 2.89Cr 37Cr 2.93Cr 2.87Cr 123.72Cr -
Net income -95.59L -82L -76.57L -70.25L -1.32Cr -91Cr -1.34Cr -9.03Cr -3.54Cr -46Cr -3.59Cr -3.51Cr -151.51Cr -51.62L -44.28L -41.35L -37.94L -71.34L -49Cr -72.51L -4.88Cr -1.91Cr -25Cr -1.94Cr -1.9Cr -82Cr
Net Debt -95.21L -81.67L -76.26L -69.97L -1.32Cr -91Cr -1.34Cr -9Cr -3.52Cr -46Cr -3.57Cr -3.5Cr -150.9Cr -40.88L -35.07L -32.74L -30.04L -56.49L -39Cr -57.42L -3.86Cr -1.51Cr -20Cr -1.53Cr -1.5Cr -65Cr
Logo Pulmatrix, Inc.
Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.
Employees
2
Date Price Change Volume
19/26/19 $1.520 -1.94% 7,823
18/26/18 $1.550 -0.64% 6,920
17/26/17 $1.560 +1.30% 12,287
14/26/14 $1.540 +1.99% 17,768
13/26/13 $1.510 -5.63% 20,612
  1. Stock Market
  2. Stocks
  3. PULM Stock